• Proven to support cell activation, retention, and proliferation 1
  • Superior handling characteristics 2
  • Optimal fit and fill:
    • ReBOSSIS® offers up to 54% compression recovery 3
    • Maintains integrity during and after placement


ReBOSSIS®, manufactured by ORTHOReBIRTH in Japan and distributed by KYOCERA, is an exciting addition to the world of biosynthetic bone scaffolding materials. This product features the handling characteristics of cotton, and enhances bone-to-graft interface. Its fibrous nature allows for easier handling and it stays where it’s placed, even after hydration. See below to learn more about this signature offering from KYOCERA.


ReBOSSIS® is the only biosynthetic bone scaffolding product with the handling and hydrophilic characteristics of cotton. Composed of β-TCP, CaCO3, silicon, and PLGA, the special formula in ReBOSSIS® contains1% silicon by weight, which is comparable to the level found in natural bone.

The interconnected networks of microporous fibers are created by a unique, proprietary manufacturing process that transforms the composite materials into a biodegradable scaffold. ReBOSSIS® is particularly effective because it absorbs and retains bioactive fluids, thereby enhancing its osteoinductive capabilities.

Indications for Use

ReBOSSIS®85 is intended for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. ReBOSSIS®85 is indicated to be packed gently into bony voids or gaps of the skeletal system (extremities, pelvis, and posterolateral spine). In the extremities and pelvis ReBOSSIS®85 may be used without hydration or hydrated with blood. In the posterolateral spine ReBOSSIS®85 is to be used hydrated with bone marrow aspirate and mixed with autograft bone. The device provides a bone void filler that is resorbed and replaced with host bone during the healing process.

Play Video

White Paper

ReBOSSIS® has undergone extensive study in laboratory settings and animal models. Please download and read the white paper on this product to read key findings related to its use in these studies.


The downloadable technical brochure below provides the fine details about ReBOSSIS®. Please review this informational pamphlet to learn about the clinical capabilities of this product.

Case Studies

ReBOSSIS® has demonstrated efficacy in a number of patients. Download our Case Studies below to read more about the outcomes of actual patients whose doctors have selected ReBOSSIS®.

Distributor Inquiries

If you have further questions or would like to receive more information about becoming a distributor for ReBOSSIS or any other Kyocera products, please complete and submit the form below.

1 Based on results of 2017 tests carried out at the Cleveland Clinic Lerner Research Institute   |  2 Based on user survey responses  |  3 Test results available upon request